» Articles » PMID: 16010426

C-erbB2-induced Epithelial-mesenchymal Transition in Mammary Epithelial Cells is Suppressed by Cell-cell Contact and Initiated Prior to E-cadherin Downregulation

Overview
Journal Int J Oncol
Specialty Oncology
Date 2005 Jul 13
PMID 16010426
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Prolonged signalling from the growth factor receptor subunit and proto-oncogene c-erbB2 has been shown to cause epithelial-mesenchymal transition (EMT) in mammary epithelial cells. Using a system where c-erbB2 homodimer signalling can be induced in human mammary epithelial cells, we characterised the properties of c-erbB2-induced EMT. The cells resulting from this transdifferentiation showed a pronounced and stable fibroblastic phenotype with spindle-like morphology, homogeneous high expression of vimentin, N-cadherin, and integrin alpha5 as well as loss of E-cadherin and desmoplakin. However, the rate at which EMT occurred was very slow compared to other reported systems, as complete conversion was not seen until after 12-15 weeks of c-erbB2 signalling. This time delay was however not due to the presence of long-lived intermediate cell types as measured by expression of combinations of markers. By studying morphological time-courses of individual colonies of epithelial cells subjected to c-erbB2 signalling, we could conclude that apart from EMT, c-erbB2 could also cause transition to very large cells retaining cell-cell contact but with little or no proliferative capacity. EMT preferentially occurred in small colonies, suggesting that extensive cell-cell contact inhibits EMT. When testing this conclusion by exposing cells to c-erbB2 signalling at different cell densities, we concluded that only cells kept at low density would undergo EMT. High cell density also prevented the proliferative decrease associated with prolonged c-erbB2 signalling. Immunofluorescence microscopy revealed that disruption of cell-cell contact was preceded by partial relocalisation of beta-catenin to the cytoplasm whereas downregulation of E-cadherin appeared to occur after initiation of cell scattering.

Citing Articles

Epithelial-Mesenchymal Transition: A Fundamental Cellular and Microenvironmental Process in Benign and Malignant Prostate Pathologies.

Goncharov A, Vashakidze N, Kharaishvili G Biomedicines. 2024; 12(2).

PMID: 38398019 PMC: 10886988. DOI: 10.3390/biomedicines12020418.


The Use of Schisandrin B to Combat Triple-Negative Breast Cancers by Inhibiting NLRP3-Induced Interleukin-1β Production.

Chang C, Liang T, Lam H Biomolecules. 2024; 14(1).

PMID: 38254674 PMC: 10813220. DOI: 10.3390/biom14010074.


A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix PC1 System.

Cohen E, Jayachandran G, Moore R, Cristofanilli M, Lang J, Khoury J Cancers (Basel). 2022; 14(21).

PMID: 36358657 PMC: 9656921. DOI: 10.3390/cancers14215238.


Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression.

Giusti V, Ruzzi F, Landuzzi L, Ianzano M, Laranga R, Nironi E Oncogenesis. 2021; 10(11):77.

PMID: 34775465 PMC: 8590694. DOI: 10.1038/s41389-021-00360-9.


Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer.

Nami B, Ghanaeian A, Black C, Wang Z Life (Basel). 2021; 11(9).

PMID: 34575017 PMC: 8472246. DOI: 10.3390/life11090868.